We have characterized the circulating inhibitor of insulin receptor binding found in several patients with a new syndrome of extreme insulin resistance. The inhibitor is an immunoglobulin by multiple criteria, including precipitation by 33% ammonium sulfate, migration on G-200 Sephadex gel filtration and DEAE chromatography, and immunoprecipitation with specific anti-human immuno-globulins. Although predominantly IgG, some activity is found in the IgM fraction of the immunoglobulins in one patient. The inhibitory immunoglobulins reacted with antisera to both kappa and lambda light chain determinants and are therefore polyclonal. In addition, activity is retained in the F(ab')2 fraction of pepsindigested IgG. Evidence suggests that these antibodies are directed at determinants on or near the insulin receptor, and that they are responsible for the observed clinical insulin resistance.
INTRODUCTION
We have previously reported six patients with an unusual syndrome of extreme insulini resistacnce in whom none of the previously know%vn catuses of insulin resistance could be identified (1) . 'Most of the patients have been femtale, rainginig in age fromii 11 to 49 yvr, and have suffered to variable degrees from the skin condition acanthosis nigricans. Glucose tolerance ranged from nornmal to severely imptaired. Insulin levels, both basal and stimulated, were elevated 10 to 100-fold, aind insulin resistance wvas miarked wheni directly assessed b) insulini tolerance A portion of this work was presented at the National Meeting of the American Society for Clinical Investigation, 3 May, 1976 (Clin. Res. 24: 457) .
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Received for publicationi 13 May 1976 and in revised form 30 August 1976. testinig. In each of the patients, insulin binding to its specific memnbrane receptors on circulating m11on1ocvtes was markedly reduced (1) . The clinical feattures shared by these patients ain several simlilarpatients previously reported suggested tw\o distinct clinical syndromes, whiclh we have designated types A and B (1) . Type A patients have been youniger femiales with sigins of virilization or accelerated growth, in whom the receptor defect may' be prim-ary. T pe B patients have been older, and have had a variety of clinical features stuggesting an autoimmune disease, including leuikopenia, hyperglobulinemia, arthralgias, and antintclear and anti-DNA antibodies. This prompted it search for a circulating antibody that might alter insulin receptor function. In a previous communication Xwe demiionstrated that plasma of these three patients contained a factor or factors thait couild specifically, reduce insulin binding after brief expostire to nornmal cells or membranes (8) . In this report wve demonstrate the immunoglobulin nature of this inhibitor, and present its preliminary characterization.
MI ETHODS
All sera were obtained after an overnight fast and were stored at -20°C until use. A 33% ammonium sulfate precipitate was prepared bv addition of drops of a saturated solution of amiimonium sulfate to serum at 4°C with conistaint shaking. After 1 h, the precipitate was sedimented at 10,000 g for 60 min. The precipitate was resuspended in 0.15 NM phosphate-buffered saline (PBS),' and both supernatant and resuspended precipitate were dialyzed for 48 h against 200 vol of PBS at 4°C. 95% of the IgG was found within the precipitate as determined by quantitative immunoelectrophoresis. Sera were fractionated by gel filtration and DEAE chromatography as described in the legends.
Preparation of F(ab')2 fraction of IgG. 4 mg of IgG (DEAE peak 1, see (potassium phosphate buffer) at pH 8 and dialyzed against 1 liter of the buffer at 4eC. The sample was then applied to a DEAE cellulose (DE52, Whatman) column (1.5 x 30 cm) that had been equilibrated in the same buffer, and 3-ml samples were collected. Most of the IgG molecules eluted with 60 ml of this buffer (DEAE peak 1). The remaining immunoglobulins (DEAE peaks 2 and 3) were eluted with a linear salt gradient developed with 0.5 M NaCl. The immunoglobulins in the various fractions were characterized by immunodiffusion in agar with specific rabbit anti-human immunoglobulin antibodies. The first peak appeared to be mainly IgG with a yield of 6 mg/ml of serum. 0.2 M sodium acetate buffer with 0.5 N NaCl, pH 4.5, containing 80 ,g of pepsin (9) . After 24 h, the pH was adjusted to 8.0 with 1 N NaOH, and the solution was dialyzed against a solution containing 0.1 M Tris HCI and 0.5 M NaCl, pH 7.4, for 24 h. The F(ab')2 fraction was separated from undigested IgG by gel filtration on G-200 Sephadex (Pharmacia Fine Chemicals, Inc., Piscataway, N. J.). The F(ab')2 nature of the fragment was confirmed by gel immunodiffusion and immunoprecipitation with specific anti-human IgG antibodies directed at the Fab and Fc fractions of the IgG molecule. Protein concentrations of the ammonium sulfate fraction, purified IgG, and F(ab')2 were determined by the method of Lowry et al. (10) with a human immunoglobulin standard.
Immunoprecipitation. Rabbit antisera to human IgG (y chain, Fab or Fc-fragment specific), IgM (,-chain specific), IgA (ca chain-specific), and light chain (K and X-specific) were purchased from Behring Diagnostics (American Hoechst Corp., Somerville, N. J.). Immunoprecipitation curves were obtained by mixing increasing amounts of anti-human immunoglobulin of indicated specificity with a constant amount of an appropriate dilution of serum or column eluate, with the total volume kept constant by addition of PBS. An incubation at 37°C for 60 min was followed by 24 h at 4°C, after which the immune precipitate was sedimented at 4°C at 2,000 rpm for 20 min in an International model PR-1000 centrifuge (Damon/IEC Div., Damon Corp., Needham Heights, Mass.). A sample of the supernatant from each tube was assayed for inhibition of insulin binding. The precipitate was washed twice at 4°C with PBS, pH 7.6, and the absorbance at 280 nm of the resuspended precipitate was determined. Insulin binding studies. Porcine insulin (Eli Liily & Company, Indianapolis, Ind.) was iodinated to a sp act of 100-200 ,uCi/,g by a modification of the chloramine-T method (11) . Human lymphoblastoid cells (IM-9), maintained in continuous culture in plastic flasks, were grown to stationary phase at 37°C in Eagle's minimum essential medium (NIH Media Unit) supplemented with 10% fetal calf serum, penicillin, and streptomycin. Glutamine (0.29 mg/ml) was added to the medium just before transfer of cells on the day of feeding. Cells were split twice a week and fresh medium was added. Viability of cells was monitored by trypan blue dye exclusion and was always greater than 90%o. We have previously shown that insulin receptors on these cells (12) have binding properties essentially identical to those of insulin receptors on circulating human monocytes (13) , as well as more classical targets of insulin action such as liver (14) and fat (15) . For this assay, IM-9 cells were sedimented and resuspended at a concentration of 15 x 106 cells/ml in an assay buffer containing 100 mM Hepes, 120 mM NaCl, 1.2 mM MgSO4, 2.5 mM KCI, 10 mM glucose, 1 mM EDTA, and 1% bovine serum albumin, pH 7.6. A 0.2-ml cell suspension was incubated for 1 h at 4°or 22°C with 0.2-ml samples of either serum or partially purified immunoglobulin at dilutions indicated in the figure legends. After 1 h, cells were washed three times with 1 ml of PBS at 4°C. The cell pellet was resuspended in 0.5 ml of assay buffer containing 100 pg of 125I-insulin and incubated for 90 min at 15°C. In every case, duplicate sets of tubes were prepared, one set of which also contained unlabeled insulin to give a final concentration of 10 ,ug/ml. At the end of the incubation, duplicate 200-,l aliquots were layered onto 100 ,ul of cold buffer in microfuge tubes and centrifuged in a Beckman microfuge (Beckman Instruments, Inc., Spinco Div., Palo Alto, Calif.) for 1 min. The supernatant was aspirated and discarded and the radioactivity in the pellet was, determined. Specific 1251-binding was considered to be the difference between tracer binding in the absence and presence of 10 ,ug/ml of unlabeled insulin.
RESULTS
Serum from three patients with insulin resistance and evidence for a circulating inhibitor of insulin receptor binding were studied. The titers of the circulating inhibitor in these sera varied over a wide range. Titers, expressed as that dilution of serum which depressed by 50%o the binding of 125I-insulin to 3 x 106 cells, ranged from 1/2 to 1/4,000 ( Fig. 2 ) and correlated well with the degree of insulin resistance in these patients, as assessed by the intravenous insulin tolerance test (1) . In one patient studied on two occasions 1 yr apart (B-2 1974 and 1975), the titer increased 10-fold. Anti-Insulin Receptor Antibodies Dilution of Serum FIGURE 2 Titers of insulin-binding inhibitor in patient sera. 3 x 10' IM-9 lymphocytes were incubated for 60 min at 22°C in a volume of 0.4 ml with serum dilutions as indicated or with buffer. Cells were then washed three times with 1 ml of PBS, pH 7.6, at 4°C, and then resuspended in two sets of tubes containing 0.5 ml of assay buffer, to which was added 100 pg of '251-insulin. One set of tubes contained in addition 10 ,ug/ml unlabeled insulin. Cells and insulin were incubated for 90 min at 15°C, after which duplicate 200-,u samples were centrifuged through 100
Al of cold buffer in a Beckman microfuge for 1 min, the supematant was aspirated, and the '251-insulin bound to the pellet was determined. Specific 1251-insulin binding was considered to be the difference between tracer binding in the absence and presence of 10 ,ugg/ml of unlabeled insulin. The percent of control binding was calculated by dividing the percent bound to antibody-treated cells by the percent bound to buffer-treated cells and multiplying by 100.
The circulating inhibitor appeared to be an immunoglobulin by multiple criteria. First, the inhibitor was quantitatively precipitated by 33% (NH4)2SO4 in each of these three sera. Studies of inhibition of insulin binding with the reconstituted 33% (NH4)2SO4 fraction (which contained more than 95% of the immunolgobulins) were superimposable with those obtained with whole serum (Fig. 3 ). When calculated per microgram of protein, the inhibitory activity was concentrated three-to fivefold in the reconstituted precipitates. No significant inhibitory activity remained in the supernatant fraction (data not shown).
To further localize the inhibitory activity, sera were fractionated on columns of G-200 Sephadex. Three main protein peaks were seen. The first is known to contain primarily IgM with some a2 macroglobulins, the second peak is mainly IgG (plus some IgA and IgE), and the third peak is primarily albumin and some globulins with mol wts less than 100,000 (16) . With serum B-2, the entire activity coeluted with the "IgG" peak. No activity was present in the prominent IgM fraction or in the peak albumin tubes (Fig. 4 ). With serum B-3, the main inhibitory activity again coiresponded to the IgG peak; however, some activity clearly coeluted with the macroglobulin peak as well ( Fig. 4 ). Immunoprecipitation experiments carried out on fractions from the G-200 separation of serum B-3 suggested that the inhibitory activity of the macroglobulini peak was due to IgM immunoglobulins ( Fig. 5 ). Thus, the inhibition of binding caused by a sample from the macroglobulin peak (fraction 18) was almost entirely abolished by immunoprecipitation with increasinig amounits of aniti-humani IgNI antisera, while additioni of antihumiian IgG had no effect. Conversely, the inhibitory activity of the IgG peak (fraction 23) was entirely eliminated by immunoprecipitation with anti-IgG, but not at all by anti-IgM. The inhibitory activity of serum B-1 was too low to permit an accurate evaluation of column fractions.
The immunoglobulin nature of the inhibitor was further suggested by the results of the DEAE fractionation. Insuliin binding was inhibited by peaks 1, 2, and 3 from the DEAE fraction of the ammonium sulfate precipitate of serum from patient B-2 ( Fig. 6 ). All three peaks contained IgG by immunodiffusion, although the concentration of IgG and inhibitory activity was much higher in peak 1 than in the later peaks. The inhibitory activity again could be neu- After 60 min at 22°C, cells were washed twice in 1 ml of PBS at 40C, and then resuspended in 0.5 ml of assay buffer for insulin binding assay as described in legend to Fig. 2 . Percent inhibition of binding was calculated as: [1 - (% specifically bound to antibody-treated cells/% specifically bound to buffer-treated cefsI1 x lX.
tralized by adding to the IgG containing fraction anti-IgG with specificity for either the Fab or Fc portion of the molecule (Fig. 7) . When the specific inhibitory activities of the various preparations of immunoglobulin from serum B-2 were compared ( Fig. 6 ), a progressive increase in activity during the purification was evident. Thus, 50% inhibition of binding occurred with 110 Ag of plasma protein, with 20 gg of the ammonium sulfate precipitate, and with 18 Ag of the IgG of DEAE peak 1. The second DEAE peak, shown by gel diffusion to contain some IgG, produced a 50o inhibition of binding with 46 ,ug of protein. For comparison, in the same assay, porcine insulin produced 50% inhibition of tracer binding at a concentration of 15 ng/ml. Further evidence that the entire inhibitory activity of the patients serum was immunoglobulin in nature was provided by immunoprecipitation studies with whole serum. Specific immunoprecipitation of serum B-2 with rabbit anti-human IgG completely depleted the serum of inhibitory activity, while anti-human IgA and IgM were without effect (Fig. 8) . These findings correlate well with the patterm observed on G-200 Sephadex and DEAE fractionation (vide supra). In addition, precipitation with both specific anti-K and anti-X antisera removed inhibitory activity from serum (Fig. 8 ). Anti-K antisera removed 40% of the activity, and anti-X removed 65%. Immunoprecipitation of serum B-3 with anti-human IgG removed a maximum of 85% of the inhibitory activity ( Fig. 9 ). Anti-IgA and anti-IgM antisera had no significant effect on binding inhibition produced by whole serum, although the amounts of these immunoglobulins precipitated were not great in these experiments. Further, the gel filtration experiments suggested that only a small fraction of the activity detected in serum was due to IgM and it may well be impossible to detect the depletion of this amount of the activity under these experimental conditions.
To prove that the IgG-mediated inhibition of insulin binding is mediated by the F(ab')2 portion of the molecule, and not through Fc binding, F(ab')2 fragments were obtained by peptic digestion of IgG. The F(ab')2 fragments clearly inhibited insulin binding. This inhibition was completely prevented by prior immunoprecipitation with anti-IgG with F(ab')2 specificity but not with anti-IgG directed at the Fc region (Fig. 7) . The mixtures were incubated at 37°C for 60 min and then at 4°C for 24 h, after which the immune precipitates were sedimented at 2,000 rpm for 20 min. 100-,ul samples of the supernatants from each tube were then incubated with 3 x 106 IM-9 lymphocytes in 0.4 ml of assay buffer at 22°C for 60 min, washed twice with 1 ml of PBS, and then resuspended in 0.5 ml of assay buffer for insulin-binding assay. Percent of control binding was calculated as described in legend to Fig. 2 . with specificity for the F(ab)2 or Fc regions, or with PBS alone for 1 h at 370C. Immune precipitates were sedimented, and duplicate 50-,ul samples of the supematants were assayed for inhibition of insulin binding as described above.
Anti-Insulin Receptor Antibodies

DISCUSSION
Immunologically mediated insulin resistance has generally been equated with the development of antibodies to exogenously administered insulin (17) . Such anti-insulin antibodies may cause insulin resistanice in a small percentage of insulin-treated diabetics, but in the vast majority of diabetics the antibodies are too low in affinitv or capacity to have any clinical effect.
We have recently described a group of diabetic patients with severe insulin resistance (1, 8) . The patients had several features suggestive of an auitoimmune illness. However, anti-insulin antibodies were undetectable or of sufficiently low titer to excltude an etiologic role in insulin resistance. In addition, direct studies of insulin binding to receptors on circulatinig monocvtes of these patients suggested a defect at the level of the insulin receptor (1, 8) . We previously demonstrated that the decrease in insulin bindin-g was due to a circulating factor that could reprodtuce the binding defect with instulin receptors on normal 1446 J. S. Flier, C. R. Kahn, D. B. Jarrett, and J. Roth cells or membranes (8) . Using a variety of techniques, we have now demonstrated that the circulating inhibitor of insulin receptor binding in these patients is an immunoglobulin. In each serum, the inhibitory activity was quantitatively recovered in the 33% ammonium sulfate precipitate, a fraction known to contain most of the immunoglobulins of sernim. The inhibitory activity of this fraction diluted stuperimposably with the activity of whole sertim, suggesting identity of the activity in these two fractions.
In the two sera with the highest titers, characterization of the activity was confirmed by gel filtration and immunoprecipitation techniques. In serum B-2, essentially all of the activity co-migrated in the "IgG" region on a G-200 Sephadex column, with no activity coincident with the macroglobulin peak.
Immunoprecipitation of this serum with specific anti-human immunoglobulins confirmed these findings, since all activity was removed by anti-IgG and none by anti-IgM or IgA antisera. The inhibitory activity of this serum was dep precipitation with antisera directec light chain determinants, showing antisera will remove a fraction of Anti-lgM 1975, were incubated with various am immunoglobulin antisera of indicated volume of 500 ul. The mixture was in 60 min and then at 4°C for 24 h, after precipitate was sedimented at 2,000 rt precipitate was washed twice with P1 OD at 280 nM of the resuspended pr mined. A 100-,u sample of the sup tube was then incubated with 3 x 100 1 0.4 ml of assay buffer at 22°C for 6 cells were washed twice with PBS, an in 0.5 ml of assay buffer for insulin bii inhibition ofbinding was calculated as de to Fig. 4 . The percent activity remainir (% inhibition after immunoprecipitation immunoprecipitation) x 100. icubated at 37°C for cytes and circulating human monocytes, rat adipowhich the immune cytes and hepatocytes, and avian erythrocytes (8) .
pm for 20 min. The Such an effect might be caused by binding to the BS, pH 7.6, and the insulin receptor itself or to a closelv linked memrecipitate was deter-brane structure. Although no evidence exists for the xematunt from each [M-9 lymphocytes in latter possibilitv, it cannot be iruled out until the re-i0 min. after which ceptor is isolated in pure form. In addition, the bindid then resuspended ing inhibition is quite specific for the insulin rending assay. Percent ceptor. Hunman growth hormone binding to its rescribed in the legend ceptor on IM-9 lymphocytes is unaffected by serum ig was calculated as:
I% inhibition before mcubations that markedly impair insulin binding to these cells (8) . Similarly, the binding of labeled Anti-Insulin Receptor Antibodies 1447 100 80 1l13UllWJlL~33iUlW 1ii3u11a1-111% alLL V ILJUVLLY UD1UU1/, a JV.,tide isolated from human serum, to its receptor on liver membranes is unaffected by sera that markedly impair insulin binding to its receptor on these same membranes.2 Studies of antibody interaction with isolated adipocytes also suggest binding determinants closely related to the insulin receptor (18) . All three antibody-containing sera and their partially purified immunoglobulin fractions specifically impair insulin binding to its receptors on isolated rat adipocytes. These antibodies also show a variable ability to stimulate glucose oxidation and to block insulin stimulation of this biological process (18) . This suggests that the antibody and insulin interact with the receptor similarly.
A previous report by Field et al.
(2) describes a patient with a clinical syndrome similar to that of our patients. In this case, insulin-like biological activity was found in the immunoglobulin fraction of serum, but could at least in part be attributed to insulin bound to anti-insulin antibodies. Several lines of evidence in the present study make it extremely unlikely that insulin, free or bound to anti-insulin antibodies, could account for the inhibition of insulin binding produced by these sera or immunoglobulin fractions. Firstly, addition of very high concentrations of insulin to normal sera, or to sera with high titers of anti-insulin antibodies, caused no inhibition of labeled insulin binding under the conditions of preincubation and washes employed in these experiments. In addition, the species specificity of the inhibitory effect produced by these sera (8) is clearly different from the inhibitory effect of unlabeled insulin on 125I-insulin binding to these cells or membranes. Further, the inhibition by patients' immunoglobulins of insulin binding and the stimulation of glucose oxidation in isolated adipocytes are both blocked by anti-IgG, and not by anti-insulin antibodies (18) . Finally, the inhibitory effect persisted in several thousand-fold dilutions of serum,3 even after depletion of insulin and anti-insulin antibodies by sequential affinity chromatography on insulin Sepharose columns, followed by ammonium sulfate precipitation.4
Recent work from our laboratory using 125I-labeled immunoglobulin from these patients that has been affinity-purified on tissues rich in insulin receptors has been used to assess directly the site of antibody 2 Megyesi, K. Unpublished data. 3Direct determination of insulin levels in whole serum of patients B-2 and B-3 was made impossible by the presence of low titers of anti-insulin antibodies, which cause spuriously high values in the double antibody radioimmunoassay. Serum specimens diluted over 100-fold and immunoglobulin preparations used in these experiments had no detectable insulin by radioimmunoassay. 4Maratos-Flier, E. Unpublished data.
LIJllU1116 kIZ7/. 111Ct;b bLUUMno lllIUMU't UIld -l--l-llbUllll and '25I-immunoglobulin bind in a parallel manner to a variety of tissues containing insulin receptors, and that labeled antibody binding is specifically competed for by insulin and insulin analogues in direct proportion to their affinity for the insulin receptor. Thus, insulin and antibody directly compete with each other for binding to a closely related membrane site.
Precedents exist for the development of autoantibodies directed at membrane receptors in human disease. Patients with myasthenia gravis have antibodies that bind to soluble preparations of human and rat muscle that contain receptors for the neurotransmitter acetylcholine (20) (21) (22) (23) . In some cases, these antibodies block the binding of labeled abungarotoxin (an irreversible cholinergic antagonist) to the receptor (20, 21) . With most sera, however, the antibodies leave the cholinergic binding site intact, but in some way alter receptor function (23) .
Other recent studies have also demonstrated that immunoglobulins from many patients with Graves' disease inhibit the binding of labeled thyroid-stimulating hormone (TSH) to human thyroid membranes (24) . These same immunoglobulin preparations stimulate adenylate cyclase activity in this tissue (25) (26) (27) (28) , and when administered to test animals, stimulate thyroid hormone release (29, 30) . Thus, the anti-TSH receptor antibodies in Graves' disease not only block the binding of TSH but also mimic its action.
The growing evidence that anti-receptor antibodies are important in myasthenia gravis, Graves' disease, and now in one variety of insulin-resistant diabetes raises two interesting questions. Firstly, by what mechanism do these unusual antibodies develop? Is the receptor a victim of a state of altered immunologic reactivity, or did some primary or induced receptor defect directly stimulate the observed antibody response? Second, we might wonder, as suggested by Lennon and Carnegie (31), whether some property of membrane receptors makes them particularly likely to be the objects of an immune response. If this were true, we would expect to find additional examples of receptor dysfunction mediated by anti-receptor antibodies.
The incidence of anti-insulin receptor antibodies among insulin-resistant patients is not yet established. In preliminary studies (32), we have found such antibodies in 7 of 16 cases of extreme insulin resistance, in whom no other causes could be demonstrated, but not in 70 additional sera from patients with diabetes, autoimmune diseases, and conditions in which other anti-receptor antibodies have been described. Whatever their incidence, these antibodies suggest new models for the pathogenesis of other states of hormone resistance and should serve as a powerful probe in further studies of the insulin receptor. 
